Details of the Drug Combination

General Information of Drug Combination (ID: DC0U7CU)

Drug Combination Name
Ibuprofen Atorvastatin
Indication
Disease Entry Status REF
Osteoarthritis Phase 1 [1]
Component Drugs Ibuprofen   DM8VCBE Atorvastatin   DMF28YC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ibuprofen
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Approved [2]
Fever MG26 Approved [2]
Headache 8A80-8A84 Approved [2]
Osteoarthritis FA00-FA05 Approved [2]
Pain MG30-MG3Z Approved [3]
Patent ductus arteriosus N.A. Approved [2]
Ibuprofen Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
C-X-C chemokine receptor type 1 (CXCR1) TTMWT8Z CXCR1_HUMAN Inhibitor [13]
Interleukin-8 (IL8) TTCTE1G IL8_HUMAN Inhibitor [14]
C-X-C chemokine receptor type 2 (CXCR2) TT30C9G CXCR2_HUMAN Inhibitor [13]
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [15]
------------------------------------------------------------------------------------
Ibuprofen Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Monocarboxylate transporter 2 (SLC16A7) DTLT3UG MOT2_HUMAN Substrate [16]
Probable small intestine urate exporter (SLC17A4) DTHE530 S17A4_HUMAN Substrate [17]
------------------------------------------------------------------------------------
Ibuprofen Interacts with 9 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [18]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [19]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [20]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [20]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Metabolism [21]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [21]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [21]
Alpha-methylacyl-CoA racemase (AMACR) DEGKWJB AMACR_HUMAN Metabolism [22]
Acyl-CoA thioesterase 2 (ACOT2) DEMEPVJ ACOT2_HUMAN Metabolism [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DME(s)
Ibuprofen Interacts with 185 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Increases ADR [24]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Decreases Activity [25]
Solute carrier family 22 member 6 (SLC22A6) OTKRCBVM S22A6_HUMAN Decreases Activity [25]
Organic anion transporter 7 (SLC22A9) OTO4BJCC S22A9_HUMAN Decreases Activity [25]
Solute carrier family 22 member 11 (SLC22A11) OTAJLNJZ S22AB_HUMAN Decreases Activity [25]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Decreases Activity [25]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Expression [26]
Prostaglandin G/H synthase 1 (PTGS1) OTHCRLEC PGH1_HUMAN Decreases Activity [27]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Increases Expression [28]
Suppressor of cytokine signaling 3 (SOCS3) OTY183WJ SOCS3_HUMAN Affects Expression [29]
Ephrin type-B receptor 6 (EPHB6) OTKNN6GC EPHB6_HUMAN Affects Expression [29]
Arachidonate 12-lipoxygenase, 12R-type (ALOX12B) OTQ0BYK6 LX12B_HUMAN Affects Expression [29]
Annexin A9 (ANXA9) OTKNYMU2 ANXA9_HUMAN Decreases Expression [29]
Metastasis-associated protein MTA2 (MTA2) OTCCYIQJ MTA2_HUMAN Increases Expression [29]
Integrin beta-like protein 1 (ITGBL1) OTJDHE17 ITGBL_HUMAN Affects Expression [29]
Complement C3 (C3) OTCH5GS0 CO3_HUMAN Affects Expression [29]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [29]
Annexin A1 (ANXA1) OT5OFDJC ANXA1_HUMAN Affects Expression [29]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [29]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [29]
Peptide YY (PYY) OTXX6AF5 PYY_HUMAN Decreases Expression [29]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Affects Expression [29]
Collagen alpha-1(XI) chain (COL11A1) OTB0DRMS COBA1_HUMAN Affects Expression [29]
Annexin A3 (ANXA3) OTDD8OI7 ANXA3_HUMAN Affects Expression [29]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Expression [29]
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) OTPWI88U CEAM1_HUMAN Affects Expression [29]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [29]
Phospholipase A2, membrane associated (PLA2G2A) OT1NY7BF PA2GA_HUMAN Affects Expression [29]
Fatty acid-binding protein, adipocyte (FABP4) OT3DKFOU FABP4_HUMAN Decreases Expression [29]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Affects Expression [29]
Myelin and lymphocyte protein (MAL) OTBM30SW MAL_HUMAN Increases Expression [29]
Cadherin-3 (CDH3) OTKNLQU7 CADH3_HUMAN Affects Expression [29]
Tenascin (TNC) OTK4FSHR TENA_HUMAN Increases Expression [29]
Nitric oxide synthase 1 (NOS1) OT7M8XVG NOS1_HUMAN Affects Expression [29]
Protein PML (PML) OT6SM2GD PML_HUMAN Affects Expression [29]
Tumor necrosis factor receptor superfamily member 3 (LTBR) OT2HVZGV TNR3_HUMAN Decreases Expression [29]
Prostaglandin E2 receptor EP3 subtype (PTGER3) OTQODQUN PE2R3_HUMAN Affects Expression [29]
Protein FosB (FOSB) OTW6C05J FOSB_HUMAN Increases Expression [29]
Fractalkine (CX3CL1) OTPLGI0E X3CL1_HUMAN Affects Expression [29]
Insulinoma-associated protein 1 (INSM1) OTG8RV8E INSM1_HUMAN Decreases Expression [29]
Max dimerization protein 1 (MXD1) OTS5CTHX MAD1_HUMAN Increases Expression [29]
Desmocollin-1 (DSC1) OTNII6GZ DSC1_HUMAN Affects Expression [29]
Corneodesmosin (CDSN) OTQW4HV6 CDSN_HUMAN Affects Expression [29]
Microtubule-associated protein RP/EB family member 2 (MAPRE2) OTAE3MX4 MARE2_HUMAN Affects Expression [29]
Voltage-dependent calcium channel subunit alpha-2/delta-3 (CACNA2D3) OTEH9HGE CA2D3_HUMAN Affects Expression [29]
Secreted frizzled-related protein 3 (FRZB) OTTO3DPY SFRP3_HUMAN Affects Expression [29]
Hydroperoxide isomerase ALOXE3 (ALOXE3) OT76J52A LOXE3_HUMAN Affects Expression [29]
T-lymphocyte surface antigen Ly-9 (LY9) OT1PKGDI LY9_HUMAN Decreases Expression [29]
Transmembrane protease serine 4 (TMPRSS4) OTCCGY2K TMPS4_HUMAN Affects Expression [29]
A disintegrin and metalloproteinase with thrombospondin motifs 8 (ADAMTS8) OT2KFY1S ATS8_HUMAN Increases Expression [29]
Sulfotransferase 1E1 (SULT1E1) OTGPJ517 ST1E1_HUMAN Decreases Activity [30]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Decreases Activity [31]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Decreases Activity [31]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Decreases Activity [31]
PDZ and LIM domain protein 1 (PDLIM1) OT4EGCPG PDLI1_HUMAN Decreases Expression [11]
Excitatory amino acid transporter 5 (SLC1A7) OTVN5C6W EAA5_HUMAN Increases Expression [11]
Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2) OT8L6EGI BCAT2_HUMAN Increases Expression [11]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Increases Expression [11]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Increases Expression [11]
Cochlin (COCH) OTBEHD89 COCH_HUMAN Decreases Expression [11]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2) OTLVN68B AAKB2_HUMAN Decreases Expression [11]
NUAK family SNF1-like kinase 1 (NUAK1) OTLLHJJQ NUAK1_HUMAN Decreases Expression [11]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [11]
Ribosomal L1 domain-containing protein 1 (RSL1D1) OT3CL4R3 RL1D1_HUMAN Increases Expression [11]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1) OTERJ4VQ SO2B1_HUMAN Decreases Expression [11]
Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) OT1G9297 TFIP8_HUMAN Decreases Expression [11]
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 (GCNT3) OTQ9ALTR GCNT3_HUMAN Increases Expression [11]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Increases Expression [11]
Protein AMBP (AMBP) OTLU8GU8 AMBP_HUMAN Decreases Expression [11]
Fructose-bisphosphate aldolase A (ALDOA) OTWRFTIB ALDOA_HUMAN Increases Expression [11]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Decreases Expression [11]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [11]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Decreases Expression [11]
Alpha-enolase (ENO1) OTB1KWJS ENOA_HUMAN Increases Expression [11]
Bifunctional glutamate/proline--tRNA ligase (EPRS1) OTXK0FLB SYEP_HUMAN Increases Expression [11]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [11]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [11]
Retinoic acid receptor alpha (RARA) OT192V9V RARA_HUMAN Decreases Expression [11]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Decreases Expression [11]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Increases Expression [11]
Histone H1.2 (H1-2) OT0AVI4M H12_HUMAN Decreases Expression [11]
Aspartate aminotransferase, cytoplasmic (GOT1) OTZLM5UB AATC_HUMAN Increases Expression [11]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Affects Activity [11]
Transcription factor E3 (TFE3) OTM99ZWH TFE3_HUMAN Increases Expression [11]
Retinoic acid receptor RXR-alpha (RXRA) OTP1TBDM RXRA_HUMAN Decreases Expression [11]
Iduronate 2-sulfatase (IDS) OTZO94EO IDS_HUMAN Increases Expression [11]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [11]
DnaJ homolog subfamily B member 2 (DNAJB2) OTZHPV5M DNJB2_HUMAN Increases Expression [11]
Adenylate kinase 4, mitochondrial (AK4) OTA0T02Q KAD4_HUMAN Decreases Expression [11]
ETS domain-containing protein Elk-4 (ELK4) OTVSSEOE ELK4_HUMAN Increases Expression [11]
High affinity cationic amino acid transporter 1 (SLC7A1) OTR2ZVA8 CTR1_HUMAN Increases Expression [11]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Expression [11]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Increases Expression [11]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Affects Activity [11]
Isoleucine--tRNA ligase, cytoplasmic (IARS1) OT9WXH5N SYIC_HUMAN Increases Expression [11]
Neutral amino acid transporter A (SLC1A4) OTVODHAE SATT_HUMAN Increases Expression [11]
Nicotinamide phosphoribosyltransferase (NAMPT) OTVJR3GL NAMPT_HUMAN Increases Expression [11]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Increases Expression [11]
Sodium- and chloride-dependent glycine transporter 1 (SLC6A9) OTHRUON2 SC6A9_HUMAN Increases Expression [11]
Dipeptidyl peptidase 1 (CTSC) OT79WJZZ CATC_HUMAN Decreases Expression [11]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Increases Expression [11]
Serine/threonine-protein kinase SIK1 (SIK1) OT6FCHME SIK1_HUMAN Increases Expression [11]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [11]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Increases Expression [11]
1,4-alpha-glucan-branching enzyme (GBE1) OTK2N05B GLGB_HUMAN Increases Expression [11]
Adenylate cyclase type 1 (ADCY1) OTSLLFZO ADCY1_HUMAN Decreases Expression [11]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Decreases Expression [11]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [11]
kinase isozyme 4, mitochondrial (PDK4) OTCMHMBZ PDK4_HUMAN Increases Expression [11]
Dual specificity protein phosphatase 5 (DUSP5) OTH96RA7 DUS5_HUMAN Increases Expression [11]
Laminin subunit alpha-3 (LAMA3) OTFME7HT LAMA3_HUMAN Decreases Expression [11]
Tumor protein D53 (TPD52L1) OTSA6U0I TPD53_HUMAN Increases Expression [11]
Glycerol-3-phosphate acyltransferase 3 (GPAT3) OTJUGPK0 GPAT3_HUMAN Increases Expression [11]
RRP12-like protein (RRP12) OTQQAEH4 RRP12_HUMAN Increases Expression [11]
Arginine/serine-rich coiled-coil protein 2 (RSRC2) OTLE0KQM RSRC2_HUMAN Increases Expression [11]
Dipeptidyl peptidase 9 (DPP9) OTBMZW2O DPP9_HUMAN Increases Expression [11]
Extracellular sulfatase Sulf-2 (SULF2) OTIXMUVL SULF2_HUMAN Decreases Expression [11]
Probable ATP-dependent RNA helicase DHX37 (DHX37) OTM1A5KP DHX37_HUMAN Increases Expression [11]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Increases Expression [11]
Pantothenate kinase 1 (PANK1) OT2CZVRT PANK1_HUMAN Increases Expression [11]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1) OT0HYZIU S3TC1_HUMAN Increases Expression [11]
Sortilin-related receptor (SORL1) OTQ8FFNS SORL_HUMAN Decreases Expression [11]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Decreases Expression [11]
Carboxymethylenebutenolidase homolog (CMBL) OT8H3S3G CMBL_HUMAN Decreases Expression [11]
Protein FAM89A (FAM89A) OTNASAXT FA89A_HUMAN Increases Expression [11]
Protein FAM210B, mitochondrial (FAM210B) OT2QHEQ6 F210B_HUMAN Decreases Expression [11]
Spermatid perinuclear RNA-binding protein (STRBP) OTU7XLZL STRBP_HUMAN Increases Expression [11]
Perilipin-2 (PLIN2) OTRXJ9UN PLIN2_HUMAN Increases Expression [11]
ETS-related transcription factor Elf-4 (ELF4) OT167PR5 ELF4_HUMAN Increases Expression [11]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [11]
Ferroptosis suppressor protein 1 (AIFM2) OT57XWXO FSP1_HUMAN Increases Expression [11]
Angiopoietin-related protein 4 (ANGPTL4) OTQL5SPX ANGL4_HUMAN Increases Expression [11]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [11]
Dual specificity protein phosphatase 22 (DUSP22) OTEZ3U85 DUS22_HUMAN Increases Expression [11]
Phospholipase A and acyltransferase 2 (PLAAT2) OTI5RMWB PLAT2_HUMAN Increases Expression [11]
Leucine--tRNA ligase, cytoplasmic (LARS1) OT4557NF SYLC_HUMAN Increases Expression [11]
Mitochondrial fission process protein 1 (MTFP1) OT3L6F7U MTFP1_HUMAN Increases Expression [11]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Increases Expression [11]
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (ARFGEF2) OTM3CQZT BIG2_HUMAN Increases Expression [11]
Protein piccolo (PCLO) OTXJZZ98 PCLO_HUMAN Increases Expression [11]
Prostaglandin reductase 1 (PTGR1) OTMAR351 PTGR1_HUMAN Affects Activity [32]
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) OTLF4ZB1 IKKA_HUMAN Decreases Activity [33]
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21) OT3EDGXO TNR21_HUMAN Decreases Expression [34]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [35]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Increases Expression [36]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Decreases Expression [37]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [38]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Increases Phosphorylation [39]
L-lactate dehydrogenase B chain (LDHB) OT9B1CT3 LDHB_HUMAN Affects Expression [40]
Annexin A2 (ANXA2) OTFNS0CC ANXA2_HUMAN Affects Expression [40]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Increases Expression [41]
Tumor necrosis factor receptor superfamily member 16 (NGFR) OTPKSM49 TNR16_HUMAN Increases Expression [42]
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Increases Expression [36]
Galectin-1 (LGALS1) OT8LDFWR LEG1_HUMAN Affects Expression [40]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Expression [43]
Heat shock cognate 71 kDa protein (HSPA8) OTJI2RCI HSP7C_HUMAN Affects Localization [44]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Increases Expression [45]
Platelet glycoprotein 4 (CD36) OT5CZWKY CD36_HUMAN Increases Expression [46]
Interleukin-1 receptor antagonist protein (IL1RN) OT308CBE IL1RA_HUMAN Decreases Secretion [47]
Phosphoglycerate mutase 1 (PGAM1) OTZ5DB06 PGAM1_HUMAN Increases Expression [40]
Peroxiredoxin-6 (PRDX6) OTS8KC8A PRDX6_HUMAN Affects Expression [40]
Peroxiredoxin-2 (PRDX2) OTLWCY9T PRDX2_HUMAN Increases Expression [40]
Solute carrier family 15 member 1 (SLC15A1) OT1P16B5 S15A1_HUMAN Affects Binding [48]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Increases Expression [49]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Increases Expression [49]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Decreases Expression [40]
Beta-secretase 1 (BACE1) OTCA7B6A BACE1_HUMAN Decreases Expression [50]
Triosephosphate isomerase (TPI1) OT14KP4B TPIS_HUMAN Increases Expression [40]
GTP-binding nuclear protein Ran (RAN) OT2TER5M RAN_HUMAN Affects Expression [40]
Peptidyl-prolyl cis-trans isomerase A (PPIA) OTHJMWQQ PPIA_HUMAN Affects Expression [40]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [51]
POU domain, class 5, transcription factor 1 (POU5F1) OTDHHN7O PO5F1_HUMAN Decreases Expression [52]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Decreases Activity [53]
Plectin (PLEC) OTU4XDEG PLEC_HUMAN Increases Expression [40]
Receptor tyrosine-protein kinase erbB-4 (ERBB4) OT9L6C41 ERBB4_HUMAN Affects Cleavage [54]
ELAV-like protein 1 (ELAVL1) OTY55PLY ELAV1_HUMAN Increases Expression [39]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Expression [12]
Sodium-coupled monocarboxylate transporter 1 (SLC5A8) OTA0WELF SC5A8_HUMAN Decreases Activity [55]
Methylcytosine dioxygenase TET1 (TET1) OTZDHT1D TET1_HUMAN Increases Expression [52]
ATP-dependent RNA helicase DDX1 (DDX1) OT3U8FD0 DDX1_HUMAN Affects Expression [40]
Endothelial PAS domain-containing protein 1 (EPAS1) OTRE3O8U EPAS1_HUMAN Decreases Expression [12]
DNA (DNMT3A) OTEJP0GH DNM3A_HUMAN Decreases Expression [52]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Response To Substance [56]
Arylamine N-acetyltransferase 2 (NAT2) OTBPDQOY ARY2_HUMAN Increases ADR [24]
Lymphotoxin-alpha (LTA) OTUC3S76 TNFB_HUMAN Affects Response To Substance [57]
------------------------------------------------------------------------------------
⏷ Show the Full List of 185 DOT(s)
Indication(s) of Atorvastatin
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [4]
Angina pectoris BA40 Approved [4]
Arteriosclerosis BD40 Approved [4]
Cardiovascular disease BA00-BE2Z Approved [5]
Coronary atherosclerosis N.A. Approved [4]
Hypercholesterolaemia 5C80.0 Approved [4]
Hyperlipidemia 5C80.Z Approved [6]
Hyperlipidemia, familial combined, LPL related N.A. Approved [4]
Hypertriglyceridemia 5C80.1 Approved [4]
Inflammation 1A00-CA43.1 Approved [4]
Non-insulin dependent diabetes 5A11 Approved [4]
Psoriasis EA90 Approved [4]
Type-1/2 diabetes 5A10-5A11 Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [7]
Stroke 8B20 Investigative [4]
Venous thromboembolism BD72 Investigative [4]
Atorvastatin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [61]
HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway) TTDJB68 N.A. Inhibitor [62]
------------------------------------------------------------------------------------
Atorvastatin Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [63]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [64]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [65]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [66]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [67]
Monocarboxylate transporter 1 (SLC16A1) DT342ZG MOT1_HUMAN Substrate [68]
Monocarboxylate transporter 2 (SLC16A7) DTLT3UG MOT2_HUMAN Substrate [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Atorvastatin Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [21]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [69]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [70]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [71]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [72]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [73]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Atorvastatin Interacts with 93 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Increases ADR [24]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Activity [74]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Decreases Expression [75]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Increases Expression [76]
Kinesin-like protein KIF6 (KIF6) OTDH3MR4 KIF6_HUMAN Increases Response To Substance [77]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Decreases Activity [78]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Increases Expression [79]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Expression [80]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [80]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Decreases Expression [75]
Sterol 26-hydroxylase, mitochondrial (CYP27A1) OT649C01 CP27A_HUMAN Decreases Expression [75]
Angiopoietin-2 (ANGPT2) OTEQK65P ANGP2_HUMAN Increases Expression [58]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [58]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Decreases Expression [58]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [58]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Increases Expression [58]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Activity [81]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [82]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Expression [83]
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2) OTBL2W7R GTR2_HUMAN Decreases Expression [83]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [83]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Increases Expression [84]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Increases Expression [84]
Prothrombin (F2) OTNFSM49 THRB_HUMAN Decreases Activity [85]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [86]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Increases Expression [76]
Insulin (INS) OTZ85PDU INS_HUMAN Increases Expression [87]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [59]
Interleukin-2 receptor subunit alpha (IL2RA) OT0MWCHG IL2RA_HUMAN Affects Expression [84]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [88]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [89]
Transferrin receptor protein 1 (TFRC) OT8ZPBDL TFR1_HUMAN Affects Expression [84]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Increases Expression [88]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [90]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Expression [91]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [86]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [92]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [93]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Expression [94]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases Expression [59]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Increases Expression [95]
Rho-related GTP-binding protein RhoC (RHOC) OTOLE1FT RHOC_HUMAN Decreases Localization [96]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Decreases Expression [97]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [98]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [93]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [98]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Decreases Expression [97]
Coagulation factor V (F5) OTDMZ3LT FA5_HUMAN Decreases Activity [85]
Bone morphogenetic protein 2 (BMP2) OT23T37S BMP2_HUMAN Increases Expression [88]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [93]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Increases Expression [59]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) OT2D9DOV TNR1A_HUMAN Decreases Expression [94]
Integrin alpha-X (ITGAX) OTOGIMHE ITAX_HUMAN Decreases Expression [97]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [84]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [98]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [98]
Interleukin-12 subunit alpha (IL12A) OTDQT8GI IL12A_HUMAN Decreases Expression [99]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [100]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [92]
Nicotinamide N-methyltransferase (NNMT) OTFM38GU NNMT_HUMAN Increases Expression [101]
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Decreases Expression [84]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Expression [86]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [98]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [98]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [102]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [103]
Importin subunit alpha-1 (KPNA2) OTU7FOE6 IMA1_HUMAN Affects Localization [104]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Decreases Expression [76]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [105]
Transforming protein RhoA (RHOA) OT6YOJ9N RHOA_HUMAN Decreases Activity [98]
Rho-related GTP-binding protein RhoB (RHOB) OTHQFQF7 RHOB_HUMAN Increases Expression [96]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [91]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [86]
CD83 antigen (CD83) OT1V4WQF CD83_HUMAN Decreases Expression [84]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [106]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [98]
Peroxisome proliferator-activated receptor alpha (PPARA) OTK095PP PPARA_HUMAN Decreases Expression [107]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Localization [103]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) OT7TNF0L AAPK1_HUMAN Increases Activity [101]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [105]
Serum paraoxonase/arylesterase 2 (PON2) OT55NCTD PON2_HUMAN Increases Expression [108]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Decreases Expression [87]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Expression [91]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [106]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Increases Phosphorylation [101]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Response To Substance [92]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [109]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases ADR [24]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Transport [110]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1) OTERJ4VQ SO2B1_HUMAN Increases Uptake [111]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Decreases Transport [112]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Increases Uptake [111]
Sister chromatid cohesion protein DCC1 (DSCC1) OTPUVLZT DCC1_HUMAN Affects Response To Substance [113]
------------------------------------------------------------------------------------
⏷ Show the Full List of 93 DOT(s)

References

1 ClinicalTrials.gov (NCT00411190) Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin
2 Ibuprofen FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2713).
4 Atorvastatin FDA Label
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 205945.
7 ClinicalTrials.gov (NCT04380402) Atorvastatin in COVID-19. U.S. National Institutes of Health.
8 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
9 Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther. 1993 Jan;264(1):475-9.
10 Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. J Biol Chem. 2004 Jul 2;279(27):28320-9. doi: 10.1074/jbc.M401396200. Epub 2004 Apr 26.
11 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
12 Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res. 2003 Aug 1;9(8):3150-7.
13 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
14 Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
15 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
16 Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
17 A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
18 PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
19 Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
20 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009 Dec;17(6):275-342.
23 A study on the chiral inversion of mandelic acid in humans. Org Biomol Chem. 2014 Sep 14;12(34):6737-44.
24 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
25 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
26 Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol. 2005 May;95(1-5):129-36.
27 Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther. 2005 Dec;315(3):1298-305.
28 Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J. 2006 Feb 15;394(Pt 1):317-24.
29 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
30 Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
31 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
32 Human prostaglandin reductase 1 (PGR1): Substrate specificity, inhibitor analysis and site-directed mutagenesis. Chem Biol Interact. 2015 Jun 5;234:105-13.
33 Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999 Dec 2;18(51):7389-94. doi: 10.1038/sj.onc.1203160.
34 Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene. 2001 Nov 29;20(55):7965-75. doi: 10.1038/sj.onc.1204985.
35 Effects of ibuprofen and hypoxia on neutrophil apoptosis in neonates. Biol Neonate. 2004;86(4):235-9. doi: 10.1159/000079831. Epub 2004 Jul 15.
36 Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors. Clin Pharmacol Ther. 2006 Apr;79(4):303-15. doi: 10.1016/j.clpt.2005.12.306.
37 Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005 Jun;128(Pt 6):1442-53. doi: 10.1093/brain/awh452. Epub 2005 Apr 7.
38 Upregulation of ICAM-1 expression in bronchial epithelial cells by airway secretions in bronchiectasis. Respir Med. 2008 Feb;102(2):287-98. doi: 10.1016/j.rmed.2007.08.013. Epub 2007 Oct 10.
39 The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells. Cancer Res. 2007 Dec 1;67(23):11402-10. doi: 10.1158/0008-5472.CAN-07-1792.
40 Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease. Proteomics. 2008 Apr;8(8):1595-607. doi: 10.1002/pmic.200700556.
41 Growth compensatory role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways. Life Sci. 2008 Mar 12;82(11-12):591-9. doi: 10.1016/j.lfs.2007.11.030. Epub 2007 Dec 23.
42 A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol. 2008 Feb;61(2):203-14. doi: 10.1007/s00280-007-0462-3. Epub 2007 Apr 20.
43 Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum Mol Genet. 2005 Dec 1;14(23):3673-84. doi: 10.1093/hmg/ddi395. Epub 2005 Oct 20.
44 Indomethacin and ibuprofen induce Hsc70 nuclear localization and activation of the heat shock response in HeLa cells. Biochem Biophys Res Commun. 2004 Jan 23;313(4):863-70. doi: 10.1016/j.bbrc.2003.12.018.
45 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys. 2009 Jul 15;487(2):139-45. doi: 10.1016/j.abb.2009.05.017. Epub 2009 Jun 6.
46 Regulation of CD36 expression in human melanoma cells. Adv Exp Med Biol. 2002;507:337-42. doi: 10.1007/978-1-4615-0193-0_52.
47 Indomethacin and ibuprofen effect on IL-1ra production by mononuclear cells of preterm newborns and adults. Biol Neonate. 2002 Aug;82(2):73-7. doi: 10.1159/000063090.
48 Affinity and translocation relationships via hPEPT1 of H-X aa-Ser-OH dipeptides: evaluation of H-Phe-Ser-OH as a pro-moiety for ibuprofen and benzoic acid prodrugs. Eur J Pharm Biopharm. 2011 Feb;77(2):327-31. doi: 10.1016/j.ejpb.2010.12.009. Epub 2010 Dec 13.
49 Redox-sensitive interaction between KIAA0132 and Nrf2 mediates indomethacin-induced expression of gamma-glutamylcysteine synthetase. Free Radic Biol Med. 2002 Apr 1;32(7):650-62. doi: 10.1016/s0891-5849(02)00755-4.
50 Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003 Oct 29;23(30):9796-804. doi: 10.1523/JNEUROSCI.23-30-09796.2003.
51 Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
52 Effects of Exposure to Acetaminophen and Ibuprofen on Fetal Germ Cell Development in Both Sexes in Rodent and Human Using Multiple Experimental Systems. Environ Health Perspect. 2018 Apr 16;126(4):047006. doi: 10.1289/EHP2307.
53 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
54 Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem. 2003 Aug 15;278(33):30748-54. doi: 10.1074/jbc.M304824200. Epub 2003 May 31.
55 The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. J Physiol. 2004 Jun 15;557(Pt 3):719-31. doi: 10.1113/jphysiol.2004.063859. Epub 2004 Apr 16.
56 Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther. 2006 May;79(5):407-18.
57 Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol. 2006 Nov 15;164(10):984-9. doi: 10.1093/aje/kwj294. Epub 2006 Aug 24.
58 Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005 Sep-Dec;12(5-6):233-41.
59 Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009 Sep;19(7):481-90. doi: 10.1016/j.numecd.2008.10.003. Epub 2009 Jan 26.
60 Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res. 2012 May;61(5):485-91. doi: 10.1007/s00011-012-0435-9. Epub 2012 Jan 15.
61 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
62 Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042.
63 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
64 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
65 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
66 FDA Drug Development and Drug Interactions
67 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
68 H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
69 Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
70 Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
71 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
72 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
73 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
74 Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia. 2005 Aug;60(8):747-53.
75 Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
76 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
77 [Association of a polymorphic marker Trp719Arg of KIF6 gene with effects of atorvastatin and simvastatin in patients with early ischemic heart disease]. Kardiologiia. 2011;51(9):4-12.
78 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
79 Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism. 2005 Feb;54(2):142-50.
80 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
81 The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
82 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
83 Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 2016 Jan 15;100:98-111.
84 Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
85 Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006 Nov;4(11):2397-404. doi: 10.1111/j.1538-7836.2006.02165.x. Epub 2006 Aug 14.
86 Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chem Biol Interact. 2018 May 1;287:32-40. doi: 10.1016/j.cbi.2018.04.005. Epub 2018 Apr 6.
87 Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int J Cardiol. 2011 Feb 3;146(3):319-25. doi: 10.1016/j.ijcard.2009.07.002. Epub 2009 Aug 3.
88 Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem. 2007 Aug 15;101(6):1430-8. doi: 10.1002/jcb.21259.
89 Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels. 2005 Jul;20(4):133-6. doi: 10.1007/s00380-005-0833-9.
90 Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol. 2002 Jul;17(7):540-3. doi: 10.1007/s00467-002-0860-z. Epub 2002 May 25.
91 Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway. J Appl Toxicol. 2019 Oct;39(10):1394-1404. doi: 10.1002/jat.3825. Epub 2019 Aug 18.
92 Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010 Oct 1;70(19):7699-709. doi: 10.1158/0008-5472.CAN-10-1626. Epub 2010 Sep 28.
93 Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
94 The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol. 2005 Dec 15;96(12):1699-704. doi: 10.1016/j.amjcard.2005.07.092. Epub 2005 Oct 28.
95 Statins regulate alpha2beta1-integrin expression and collagen I-dependent functions in human vascular smooth muscle cells. J Cardiovasc Pharmacol. 2003 Jan;41(1):89-96. doi: 10.1097/00005344-200301000-00012.
96 Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer. 2008 May 1;122(9):2115-24. doi: 10.1002/ijc.23315.
97 Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med. 2007;45(2):193-9.
98 RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006 Nov;13(11):1845-56. doi: 10.1038/sj.cdd.4401873. Epub 2006 Feb 10.
99 Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected]. Eur J Clin Invest. 2003 Jan;33(1):88-91. doi: 10.1046/j.1365-2362.2003.01105.x.
100 Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am Heart J. 2006 Jan;151(1):139. doi: 10.1016/j.ahj.2005.10.006.
101 Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells. J Appl Toxicol. 2021 Jul;41(7):1076-1088. doi: 10.1002/jat.4094. Epub 2020 Oct 19.
102 Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol. 2004 Apr 7;43(7):1188-94. doi: 10.1016/j.jacc.2003.10.046.
103 Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
104 Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. Viruses. 2021 Oct 15;13(10):2084. doi: 10.3390/v13102084.
105 Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
106 Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms. Can J Physiol Pharmacol. 2009 Nov;87(11):915-22. doi: 10.1139/y09-085.
107 Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol. 2011 Jul 15;662(1-3):9-14. doi: 10.1016/j.ejphar.2011.04.043. Epub 2011 May 1.
108 Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):175-80. doi: 10.1161/01.ATV.0000104011.88939.06. Epub 2003 Oct 30.
109 Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011 Dec;16(12):1268-84.
110 Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000 Feb;17(2):209-15. doi: 10.1023/a:1007525616017.
111 The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):244-50. doi: 10.1111/bcpt.12031. Epub 2012 Dec 6.
112 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.
113 Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Toxicol Appl Pharmacol. 2022 Oct 1;452:116169. doi: 10.1016/j.taap.2022.116169. Epub 2022 Aug 1.